TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06055920
Drug: Anticoagulation Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.~Anticoagulants are a group of medications that decrease your blood's ability to clot.
Study: NCT05062889
Drug: 5-Fluorouracil continuous infusion FOLFOXIRI schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3200 mg/sqm 48 h-continuous infusion, starting on day 1. To be repeated every two weeks for a maximum of 12 cycles.
Study: NCT05062889
Drug: 5-Fluorouracil continuous infusion FOLFOX schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2400 mg/sqm 48 h-continuous infusion, starting on day 1. To be repeated every two weeks for a maximum of 12 cycles.
Study: NCT05062889
Drug: L-Leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.
Study: NCT05062889
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/sqm/bid per os from day 1 to day 14. To be repeated every 3 weeks until 8 cycles. Available as 500 and 150 mg tablets.
Study: NCT05062889
Drug: Trifluridine/Tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg/m2/bid per os days 1-5 and 8-12. To be repeated every 4 weeks until 6 cycles. Available as 20 and 15 mg tablets.
Study: NCT04482062
Drug: Optimal Medical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal Medical Therapy
Study: NCT06502262
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will be given 3ml (15mg) of 0.5%hyperbaric bupivacaine +0.5ml (25 microgram) of fentanyl intrathecally
Study: NCT06701669
Drug: Cohort B: paridiprubart
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a single IV dose of 15 mg/kg up to maximum of 1440 mg on Day 1
Study: NCT06788522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo pills
Study: NCT06365879
Drug: CMAB007
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg, SC, Q4W
Study: NCT04810429
Drug: Incobotulinumoxin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: XEOMIN® (incobotulinumtoxinA) is an approved medication that inhibits the release of acetylcholine and muscle blockage. Xeomin is indicated for the symptomatic treatment of blepharospasm and hemifacial spasm, cervical dystonia of a predominantly rotational type (spasmodic torticollis), spasticity of the upper limbs and chronic sialorrhea due to neurological changes. Xeomin comes as a white powder for solution for injection. When dissolved Xeomin is a clear, colorless solution that does not contain particles. Xeomin is reconstituted before use with sterile sodium chloride 9 mg / ml (0.9%) solution, without preservatives, for injections.~The active substance is Clostridium botulinum type A neurotoxin (150 kD), without complexing proteins. The other components are human albumin and sucrose.
Study: NCT06253988
Drug: Probiotic Formula
Normalized name: Probiotic Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: intra-pocket formula (local delivery drug)
Study: NCT06253988
Drug: placebo formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: intra-pocket formula (local delivery drug)
Study: NCT06783634
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (Control group) will receive normal saline as a placebo.
Study: NCT05236517
Drug: Placebo (Semaglutide C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet given orally
Study: NCT05236517
Drug: Placebo ( Semaglutide D)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet given orally
Study: NCT06334432
Drug: NUV-1511
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel small molecule
Study: NCT06569212
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Dosing:~Placebo Injection (instructions: 5mL NS, once) Placebo Tab (1 tab PO, q12 hours, timed to start 1hr after placebo injection, 6 doses) If unable to take PO medication, Placebo Injection (instructions, 5mL q6hrs for 12 doses) Continue for 72-hours of administration unless reaching stopping criteria
Study: NCT06194825
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplontersen-matching placebo by subcutaneous injection
Study: NCT04075240
Drug: Rivaroxaban 10 MG and acetylsalicylic acid 81 mg
Normalized name: codeine and acetylsalicylic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting post op, rivaroxaban (5 days) followed by aspirin (9 days for TKA; 30 days for THA)
Study: NCT04075240
Drug: acetylsalicylic acid 81 mg
Normalized name: 5-BROMO-2-ACETYLSALICYLIC ACID 81 mg ORAL TABLET, COATED [Cardioaspirina Tabletas con cubierta enterica]
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting post op, aspirin for 9 days for TKA and 30 days for THA
Study: NCT04747314
Drug: Antidepressant
Normalized name: Antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: The antidepressant treatment utilizes antidepressant medication to improve pain, function, and depression outcomes.~The Antidepressant Treatment History Form (ATHF) will be used to assess adequacy of any prior antidepressant medication treatment and to assist the decision regarding which antidepressant to start. A medication flowchart will help serve as a guideline throughout the drug selection and dosing determination. Weekly assessments completed by subjects will help determine response, tolerability, and necessity for dose adjustment or medication change.
Study: NCT06792552
Drug: SIM0505 for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every 21 days is one cycle. Multiple dose levels of SIM0505 will be explored in dose escalation, and determine the maximum tolerated dose.
Study: NCT06792552
Drug: SIM0505 for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every 21 days is one cycle. 2-3 dose levels of SIM0505 will be explored in dose optimization, and determine the recommended dose (RD) of SIM0505 and evaluate the preliminary anti-tumor activity of SIM0505
Study: NCT06537817
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match HT-4253 Single or Multiple doses administered orally as a tablet
Study: NCT05025787
Drug: CNTX-6970
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNTX-6970, a novel potent antagonist of CCR2 with lesser effects on CCR5, is being developed as a new treatment for chronic pain, including painful osteoarthritis of the knee.
Study: NCT05025787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID
Study: NCT05890664
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo. Both the active drug and placebo will look similarly. The route and mode of administration is also similar to the active group.
Study: NCT06033222
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contains no active ingredient.
Study: NCT05460416
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 160mg once a day
Study: NCT05097950
Drug: Administration of 1 gr paracetamol I.V
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 1 gr paracetamol I.V
Study: NCT06422806
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06785090
Drug: Bromfenac
Normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromfenac is a non-steroidal anti-inflammatory drug (NSAID) formulated as a 0.09% ophthalmic solution. It is administered to reduce inflammation and prevent cystoid macular edema (CME) following cataract surgery.
Study: NCT03651895
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06584695
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive IV morphine 0.1mg/kg after induction of general anesthesia.~General anesthesia induction will be performed with fentanyl 1-2 μg/kg, propofol 2-3 mg/kg, and rocuronium 0.6 mg/kg and maintained with sevoflurane.
Study: NCT06783881
Drug: Kylo-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT06783881
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT06605599
Drug: Placebo for ABBV-932
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT05666362
Drug: benoxinate hydrochloride 0.4% group
Approvals — FDA: no, EMA: no, PMDA: no
Description: They will receive benoxinate hydrochloride 0.4% immediately before fundus
Study: NCT05666362
Drug: saline 0.9% .
Approvals — FDA: no, EMA: no, PMDA: no
Description: They will receive saline 0.9% before fundus examination in each eye .
Study: NCT05659459
Drug: KIN001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT05659459
Drug: KIN001-Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator - Oral tablet with same appearance of KIN001
Study: NCT06491446
Drug: ABI-2280
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different strength of ABI 2280 will be administered in different cohorts.~Other: Placebo Matching placebo will be administered.
Study: NCT05374512
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet. Oral route of administration. Active comparator
Study: NCT03255408
Drug: Drug Lowering Cerebral Blood Flow (CBF) and Normoxia Sleep
Normalized name: Sus scrofa cerebral cortex preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Normoxia Exposure
Study: NCT03255408
Drug: Drug Lowering CBF and Intermittent Hypoxia Sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Intermittent Hypoxia (IH) Exposure
Study: NCT03255408
Drug: Placebo and Normoxia Sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study participants will take Placebo and sleep under Normoxia Exposure
Study: NCT03255408
Drug: Placebo and Intermittent Hypoxia Sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study participants will take Placebo and sleep under Intermittent Hypoxia (IH) Exposure
Study: NCT06569758
Drug: GenSci098
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous , 5 dose levels(15mg, 45mg, 90mg, 180mg and 270mg) will be assigned.
Study: NCT06569758
Drug: GenSci098 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In SAD part only one dose of GenSci098 and GenSci098 Placebo to be given, in MAD part, GenSci098 and GenSci098 will be given on Day 1 and Day 85
Study: NCT06587802
Drug: Triprolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the end of radiotherapy, 240mg of triplizumab was administered intravenously every cycle (21 days)
Study: NCT04989803
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lymphodepleting chemotherapy administered intravenously
Study: NCT06469970
Drug: Glucose 30% Intravenous Solution
Normalized name: glucose 30% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measurement of IDVG on admission, at 4 hours (H+4), and at 8, 16, 24, 48, 72 and 96 hours (H+8, H+16, H+24, H+48, H+72 and H+96) post-burn. The principle of this measurement consists of taking a reference blood glucose level measured on an arterial blood sample (arterial catheter) using a blood glucose meter. A bolus of 5g of glucose is injected into a central venous line over 30 seconds. A second blood glucose level is measured 3 minutes after the end of the injection.~The intra-thoracic blood volume (ITBV) and extra-vascular lung water (EVLW) are measured using the PiCCO device as part of the usual management of burn patients.
Study: NCT05714553
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion
Study: NCT05183542
Drug: Bone scan
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Persons to be operated on for lumbar arthrodesis by the neurosurgery team of the Nancy CHRU and respecting the eligibility criteria (including a score of neuropathique pain scale \< 4, see non-inclusion criteria), will be proposed to participate in the study neuropathic pain If they give their oral agreement to the neurosurgeon, a request for a bone scan will be sent to the nuclear medicine department of the Nancy-Brabois Hospital. The patients will fill pain scales before and after surgery (ODI and NS)
Study: NCT05419505
Drug: CCH-aaes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection.
Study: NCT05473910
Drug: SOC + TSC-100
Normalized name: POUCH,URINARY POST-OP NU-HOPE #8254-TSC
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-1 positive
Study: NCT05473910
Drug: SOC + TSC-101
Normalized name: POUCH,URINARY POST-OP NU-HOPE #8254-TSC
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-2 positive or HA-1 negative
Study: NCT06067828
Drug: Treatment C : Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized participants will receive 2 inhalations of placebo MDI via oral inhalation BID.
Study: NCT06029426
Drug: NMRA-335140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
Study: NCT06029426
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally
Study: NCT06772753
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: inactive substance
Study: NCT05729282
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavor-approximate placebo consisting of peppermint extract in diet tonic water, thickened with xanthan gum, provided in label-obscured single-use oral syringes at 2 mg per kg per dose (total of 27 doses over 14 days).
Study: NCT04272242
Drug: Antiretroviral Therapy (ART)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants remained on DTG-based ARV treatment with 2 NRTIs (excluding TAF) during the study. NRTIs were not provided by the study. Arm 1 participants took non-study supply of DTG for morning doses, and study-supplied DTG for evening doses. For Arm 2 participants, DTG was to have come from non-study ARV supply.
Study: NCT04878354
Drug: Tree SLIT-tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual allergy immunotherapy tablets
Study: NCT04878354
Drug: Placebo SLIT-tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04721626
Drug: Tetracycline Ointment
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative: \~10g 3% tetracycline ointment will be placed into the oral cavity to coat the dorsal tongue and any oral suture lines every six hours for two days (8 total doses).
Study: NCT06599827
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: CapeOx-Capecitabine 1000 mg/m² orally twice daily (days 1-14, every 21 days) + Oxaliplatin 130 mg/m² IV (day 1, every 21 days).
Study: NCT06599827
Drug: immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serplulimab 300 mg IV infusion on day 1 every 21 days.
Study: NCT06593626
Drug: [18F]Florbetazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluate the safety of \[18F\]Florbetazine injection in AD and MCI patients, and healthy subjects.
Study: NCT05135000
Drug: LTP001
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTP001 will be administered orally once daily in the morning
Study: NCT05135000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to LTP001 will be administered once daily in the morning
Study: NCT05262842
Drug: JS001+IMP4297
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I: Dose Escalation The primary endpoints are the safety and tolerability of the combination, including the incidence and nature of DLTs and the determination of the MTD and RP2D. A 3 + 3 dose-escalation (60mg,80mg,100mg)design will be used. Patient in each dose level will be treated with toripalimab 240mg in combination with senaparib.~Phase Ib: Dose Expansion This part will commence after the RP2D is determined and will further evaluate the safety and anti-tumor activity of toripalimab and senaparib in patients with specific types of advanced solid tumors. Patients will be enrolled concurrently into 5 exploratory cohorts with approximately 20 patients each cohort.
Study: NCT05234307
Drug: Adenosine A2B Receptor Antagonist PBF-1129
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05191667
Drug: AN0025
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg or 500 mg Q.D., oral administration
Study: NCT05498610
Drug: NNC0480 0389
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will get 1 injections of NNC04800389. It will be injected with a needle into a skin fold on the abdomen.~The study will last for a maximum of 72 days
Study: NCT05008926
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of the placebo according to the same procedures as the experimental arm.
Study: NCT04874129
Drug: YYC506 (phase 1)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test
Study: NCT04874129
Drug: YYC506 (phase 2)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test
Study: NCT06788990
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Control
Study: NCT04527185
Drug: Endotoxin
Normalized name: Endotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endotoxin 0.4ng/kg i.v.
Study: NCT04944121
Drug: RSLV-132
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg RSLV-132 administered by intravenous infusion
Study: NCT05322525
Drug: ON101 Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug:~1. Name: ON101~2. Dosage form: Topical cream~3. Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica~4. Dose(s): Apply 1 cc per 5 cm2 ulcer size (not exceeding 2 mm in thickness)~5. Dosing schedule: Apply once a day
Study: NCT05306340
Drug: LHRH Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only premenopausal/perimenopausal female participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
Study: NCT04607668
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose 5% in water or normal saline (sodium chloride solution 0.9%) administered by IV infusion over 30 (±10) minutes no more than 4 hours prior to each Day 1 chemotherapy administration. Second dose of placebo was administered on Day 2.
Study: NCT06600347
Drug: Anti hypertensive drugs
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants in all groups will be treated with antihypertensive drugs as prescribed from the physician
Study: NCT04714320
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 757456 matching placebo administered by SC injection.
Study: NCT06621251
Drug: TRL1068 (calpurbatug), a human monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody
Study: NCT04977778
Drug: Fatty Acids Compounds (F.A.G.) Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fatty Acids Compounds (F.A.G.) Mouthwash
Study: NCT04120766
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching tablet
Study: NCT04720157
Drug: ARDT
Normalized name: CHLAMYDOMONAS REINHARDTII
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally on a continuous basis as per package insert and guideline
Study: NCT04720157
Drug: ADT
Normalized name: Radtue
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT are administered as per physician order
Study: NCT06185452
Drug: Hospital long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital administration of long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg as standard of care.
Study: NCT06185452
Drug: Out of Hospital long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Out of Hospital administration of long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg as an optional therapy in HIV-Infected patients from Spain.
Study: NCT06790212
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine，1000mg/m2，po，BID，D1-D14，Q3W
Study: NCT05535946
Drug: ABX464
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once daily, preferably in the morning, with food
Study: NCT05535946
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once daily, preferably in the morning, with food
Study: NCT05700669
Drug: AsiDNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive a loading dose of AsiDNA intravenously (D1, D2, D3) followed by weekly intravenous administrations in combination with Olaparib.
Study: NCT05002868
Drug: RP12146
Approvals — FDA: no, EMA: no, PMDA: no
Description: starting dose of 100 mg QD
Study: NCT05719311
Drug: adrulipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric microgranule formulation of adrulipase.
Study: NCT06124378
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy from Day 1 to Day 14 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for capecitabine-induced toxicity was implemented according to the study in British Journal of Cancer (2018) 118:1322-1328.
Study: NCT06221722
Drug: Regular treatment of functional constipation
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: at least 3 months of continuous regular treatment. This treatment included the utilization of osmotic laxatives, stimulant laxatives, prosecretory agents, and a high-fibre diet.
Study: NCT06221722
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine oral treatment for 4 weeks.